IPA
Income statement / Annual
Last year (2024), ImmunoPrecise Antibodies Ltd.'s total revenue was $24.52 M,
an increase of 18.65% from the previous year.
In 2024, ImmunoPrecise Antibodies Ltd.'s net income was -$27.18 M.
See ImmunoPrecise Antibodies Ltd.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
04/30/2024 |
04/30/2023 |
04/30/2022 |
04/30/2021 |
04/30/2020 |
04/30/2019 |
04/30/2018 |
04/30/2017 |
04/30/2016 |
12/31/2014 |
| Operating Revenue |
$24.52 M |
$20.67 M |
$19.36 M |
$17.91 M |
$14.06 M |
$10.93 M |
$5.44 M |
$2.63 M |
$1.90 M |
$1.76 M |
| Cost of Revenue |
$12.47 M
|
$9.10 M
|
$8.38 M
|
$6.37 M
|
$6.02 M
|
$5.63 M
|
$2.99 M
|
$1.21 M
|
$0.00
|
$265.33 K
|
| Gross Profit |
$12.05 M
|
$11.56 M
|
$10.98 M
|
$11.54 M
|
$8.03 M
|
$5.30 M
|
$2.45 M
|
$1.42 M
|
$1.60 M
|
$1.50 M
|
| Gross Profit Ratio |
0.49
|
0.56
|
0.57
|
0.64
|
0.57
|
0.48
|
0.45
|
0.54
|
0.84
|
0.85
|
| Research and Development Expenses |
$4.06 M
|
$14.11 M
|
$6.69 M
|
$1.97 M
|
$446.28 K
|
$485.85 K
|
$509.25 K
|
$660.41 K
|
$302.77 K
|
$621.64 K
|
| General & Administrative Expenses |
$15.59 M
|
$19.81 M
|
$16.97 M
|
$12.65 M
|
$7.95 M
|
$7.65 M
|
$6.31 M
|
$6.70 M
|
$997.29 K
|
$64.84 K
|
| Selling & Marketing Expenses |
$3.54 M
|
$3.61 M
|
$740.00 K
|
$691.00 K
|
$377.73 K
|
$819.25 K
|
$134.68 K
|
$119.19 K
|
$20.83 K
|
$6.69 K
|
| Selling, General & Administrative Expenses |
$19.14 M
|
$18.99 M
|
$17.71 M
|
$13.34 M
|
$9.03 M
|
$8.15 M
|
$5.80 M
|
$1.98 M
|
$1.02 M
|
$64.84 K
|
| Other Expenses |
$2.62 M
|
$4.08 M
|
$1.94 M
|
$475.00 K
|
$2.65 M
|
-$3.34 M
|
$256.52 K
|
$170.49 K
|
$332.58 K
|
$1.04 K
|
| Operating Expenses |
$25.82 M
|
$37.17 M
|
$27.66 M
|
$15.71 M
|
$12.08 M
|
$11.52 M
|
$7.21 M
|
$2.81 M
|
$1.66 M
|
$65.88 K
|
| Cost And Expenses |
$38.28 M
|
$46.28 M
|
$35.53 M
|
$22.09 M
|
$18.11 M
|
$17.45 M
|
$10.37 M
|
$3.92 M
|
$1.66 M
|
$1.72 M
|
| Interest Income |
$23.00 K
|
$122.00 K
|
$279.00 K
|
$282.00 K
|
$272.01 K
|
$30.09 K
|
$73.00 K
|
$0.00
|
$9.31 K
|
$0.00
|
| Interest Expense |
$19.00 K
|
$30.00 K
|
$419.00 K
|
$863.00 K
|
$1.44 M
|
$1.32 M
|
$255.78 K
|
$16.22 K
|
$9.31 K
|
$338.00
|
| Depreciation & Amortization |
$5.74 M
|
$6.69 M
|
$3.77 M
|
$3.71 M
|
$3.41 M
|
$2.26 M
|
$458.08 K
|
$50.61 K
|
$41.88 K
|
$1.04 K
|
| EBITDA |
-$22.95 M |
-$21.04 M |
-$11.99 M |
-$1.42 M |
-$449.00 K |
-$4.03 M |
-$4.35 M |
-$5.40 M |
$293.84 K |
$368.57 K |
| EBITDA Ratio |
-0.94
|
-1.02
|
-0.62
|
-0.08
|
-0.03
|
-0.37
|
-0.8
|
-2.05
|
0.15
|
0.21
|
| Operating Income Ratio |
-0.56
|
-1.24
|
-0.81
|
-0.23
|
-0.29
|
-0.6
|
-0.84
|
-0.53
|
0.13
|
-0.02
|
| Total Other Income/Expenses Net |
-$14.94 M
|
-$2.14 M
|
-$67.00 K
|
-$1.82 M
|
-$1.47 M
|
-$1.39 M
|
-$132.00 K
|
-$4.08 M
|
$221.18 K
|
-$25.10 K
|
| Income Before Tax |
-$28.70 M
|
-$27.75 M
|
-$15.85 M
|
-$6.00 M
|
-$5.29 M
|
-$7.61 M
|
-$5.06 M
|
-$5.47 M
|
$242.65 K
|
$344.07 K
|
| Income Before Tax Ratio |
-1.17
|
-1.34
|
-0.82
|
-0.33
|
-0.38
|
-0.7
|
-0.93
|
-2.08
|
0.13
|
0.2
|
| Income Tax Expense |
-$1.53 M
|
-$1.19 M
|
$861.00 K
|
$1.35 M
|
-$346.00 K
|
$4.79 K
|
$109.72 K
|
-$82.38 K
|
$91.61 K
|
$338.00
|
| Net Income |
-$27.18 M
|
-$26.56 M
|
-$16.71 M
|
-$7.34 M
|
-$4.95 M
|
-$7.62 M
|
-$5.17 M
|
-$5.38 M
|
$151.04 K
|
-$62.31 K
|
| Net Income Ratio |
-1.11
|
-1.29
|
-0.86
|
-0.41
|
-0.35
|
-0.7
|
-0.95
|
-2.05
|
0.08
|
-0.04
|
| EPS |
-1.06 |
-1.07 |
-0.85 |
-0.45 |
-0.36 |
-0.61 |
-0.57 |
-1.36 |
0.1 |
-0.11 |
| EPS Diluted |
-1.06 |
-1.07 |
-0.85 |
-0.45 |
-0.36 |
-0.61 |
-0.57 |
-1.36 |
0.1 |
-0.11 |
| Weighted Average Shares Out |
$25.64 M
|
$24.90 M
|
$19.69 M
|
$16.47 M
|
$13.63 M
|
$12.54 M
|
$9.11 M
|
$3.96 M
|
$1.92 M
|
$550.13 K
|
| Weighted Average Shares Out Diluted |
$25.64 M
|
$24.90 M
|
$19.69 M
|
$16.47 M
|
$13.63 M
|
$12.54 M
|
$9.11 M
|
$3.96 M
|
$1.92 M
|
$550.13 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
